Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | RHOA | P61586 | 2/20 | 0.38 |
| ▸ | RHOC | P08134 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | GIPR | P48546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275000 | 0.92 | EPHX2 (0.50) | EPHX2CXCR3NAMPTRHOARHOC | |
| SCHEMBL4274998 | 0.92 | EPHX2 (0.50) | EPHX2CXCR3NAMPTRHOARHOC | |
| SCHEMBL15353967 | 0.87 | CXCR3 (0.48) | EPHX2CXCR3NAMPTRHOARHOC | |
| SCHEMBL8374009 | 0.84 | CXCR3 (0.48) | EPHX2CXCR3NAMPTRHOARHOC | |
| SCHEMBL8373007 | 0.83 | CXCR3 (0.47) | EPHX2CXCR3NAMPTRHOARHOC | |
| SCHEMBL19113042 | 0.81 | EPHX2 (0.54) | EPHX2CXCR3NAMPTRHOARHOC | |
| SCHEMBL7805034 | 0.80 | MEN1 (0.45) | EPHX2CXCR3NAMPTALDH1A1GAA | |
| SCHEMBL15353987 | 0.80 | KCNH2 (0.55) | ALDH1A1KCNH2CACNA1I | |
| SCHEMBL19113271 | 0.78 | CXCR3 (0.48) | EPHX2CXCR3NAMPTRHOARHOC | |
| SCHEMBL4278127 | 0.78 | CXCR3 (0.56) | EPHX2CXCR3NAMPTRHOARHOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | EPHX2 3915/4885CXCR3 3807/4885NAMPT 1401/4885 |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | EPHX2 3915/4885CXCR3 3807/4885NAMPT 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.